about
sameAs
Clinical Applications of Circulating Tumor Cells in Lung Cancer Patients by CellSearch SystemThe activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992)Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group.An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and TreaIL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions.New perspectives for the pharmacological and biological therapy of small cell lung cancer.Ramucirumab: preclinical research and clinical development.Arginase 2 is expressed by human lung cancer, but it neither induces immune suppression, nor affects disease progression.IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer.Geography of clinical cancer research publications from 1995 to 1999.Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens.Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancerTriplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy.Performance comparison of two commercial human whole-exome capture systems on formalin-fixed paraffin-embedded lung adenocarcinoma samples.Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.Adjuvant chemotherapy for non-small cell lung cancer: ready for clinical practice?Expression of Ribonucleotide Reductase Subunit-2 and Thymidylate Synthase Correlates with Poor Prognosis in Patients with Resected Stages I-III Non-Small Cell Lung Cancer.Next-Generation Sequencing Workflow for NSCLC Critical Samples Using a Targeted Sequencing Approach by Ion Torrent PGM™ Platform.Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancerAfatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatinIdentifying an optimum treatment strategy for patients with advanced non-small cell lung cancer.Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer.Glyceraldehyde-3-phosphate dehydrogenase gene over expression correlates with poor prognosis in non small cell lung cancer patientsManagement of non-small cell lung in cancer patients with stable disease.Pleural and peripheral lung lesions: comparison of US- and CT-guided biopsy.Pemetrexed for the treatment of non-small cell lung cancer.Role of immunotherapy in the treatment of advanced non-small-cell lung cancer.Role of microRNAs in malignant mesothelioma.Afatinib for the treatment of advanced non-small-cell lung cancer.Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy.Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer.Oral vinorelbine in the treatment of non-small-cell lung cancer.Efficacy of motesanib diphosphate in non-small-cell lung cancer.Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview.Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine.
P50
Q27004790-3ED748B2-181E-4418-8841-656FC0F97BEAQ27004790-51E20694-CBD7-4C59-A422-2D59B7A99A26Q28207228-239C0A53-82C3-42CE-8215-B6DDA2CEA7B4Q28207228-7DA5FF58-764D-429B-B9FD-367D1B830505Q33370599-7FB42F53-1BF8-430B-AA63-660207EED5BAQ33370599-B0A7D27E-2FA0-410C-8D5A-DF2663684B4AQ33379422-4BF65F61-4156-4EF1-8E5B-3270AD381930Q33379936-1865A9F2-421B-43B7-9A61-4E76A06BCBCAQ33379936-DF2C27D0-16B3-4287-B533-29AE66FE49CFQ33408559-39F317C7-C0AD-4478-B14B-91CB3D347B12Q33408559-EC6419C0-C75A-443F-87EA-C8F4E20DAE14Q33408588-F1D03C32-D2ED-449D-9905-911C21DFD859Q33479161-0C5BF737-D445-4022-9896-129A6AFACA2CQ33714269-26D08709-A24E-4E53-8DE6-943D142A35D0Q33714269-BDFC7A35-2DA5-4CA9-8D53-65676B1C5760Q34446310-B119598E-DC38-4CAC-AFCD-9C2A91F490C8Q34446310-B41867ED-1BDB-4602-97CB-DFE5F9216CD6Q34784897-14939A06-E175-4C91-B716-EE04883653D7Q34980354-DC4794A0-A762-4927-83CF-1CFA2A0572F5Q35035228-8B08DE6E-B7D3-4743-A9C2-D197D7725125Q35035228-C0058B74-2961-4C2D-800F-542B389D569FQ35583723-BCD36A14-7294-49E2-8189-361127FE2976Q35583723-ECC11AE4-DCD9-49ED-B9C9-C5F5AB52F273Q35752978-5B27D524-66CE-448C-B705-9F0C35B9FF97Q35879879-13704CFA-4C63-4D23-9297-D8A59136D36AQ35879879-4F2F43E4-B06B-4F8E-9F11-94D1F807714DQ35914343-4F58ADD5-60F9-4DDC-92B3-F9A08C6C4226Q36117926-27C2A3F5-A507-4EC4-8263-B60E4C5F7DBEQ36284430-B2A77D3C-CD69-45D4-9712-862B8B166C9AQ36315282-875957BE-ECD9-4DCB-883D-4BB43B7A39BBQ36315282-CDF9B8BC-D664-4E38-AFCB-58595818B964Q36333164-A19A6F0F-1889-4F21-BC81-5AB6C865F988Q36333164-B97699CE-9DBB-4062-BF3E-05AE4A9E39F5Q36404083-4D45B7A8-6171-4F84-98D1-642F2B43E77BQ36404083-FF1851A9-A5EA-4B11-99C9-9B68BDAED886Q36619609-4AE444CE-5E6E-4B41-B9E1-4B5CED102F03Q36619609-55498304-A939-4BDF-95A4-6D3E02A9D9B9Q36627196-B7062A32-278E-4569-8748-6F9875A407E9Q36893674-5F89B0DA-4AD4-4B2A-83DB-F517FEE198B1Q37075225-8DEBA135-D7B7-46AE-AC04-256B46A086CF
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Francesco Grossi
@ast
Francesco Grossi
@en
Francesco Grossi
@es
Francesco Grossi
@nl
Francesco Grossi
@sl
type
label
Francesco Grossi
@ast
Francesco Grossi
@en
Francesco Grossi
@es
Francesco Grossi
@nl
Francesco Grossi
@sl
prefLabel
Francesco Grossi
@ast
Francesco Grossi
@en
Francesco Grossi
@es
Francesco Grossi
@nl
Francesco Grossi
@sl
P106
P1153
7006048215
P21
P31
P496
0000-0001-8412-3136